On April 17, a delegation from Pharnex, composed of Mr. Wang Bo, founder of Pharnex; Ms. Yan Jie, Chairman of Hankang Medicine, Ms. Lu Donghong, Technical Deputy Director of the All-China Federation of Industry and Commerce and representatives of nearly 20 leading pharmaceutical companies in the fields of pharmaceutical investment, innovative drug research and development, import and export trade, came to Leadingpharm for visit and communication. Mr. Tao Xinhua, chairman of Leadingpharm, Mr. Liu Kun, executive vice president, received and made in-depth exchanges with all parties.
 

Guests firstly visited Leadingpharm’s R & D laboratory, and listened to the introduction of Leadingpharm, experienced the layout of Leadingpharm CXO Industry Chain.
 

At the following forum, Chairman Tao warmly welcomed the delegation. Tao said that new drug development has entered a fully competitive stage, requiring a perfect combination of scientists and entrepreneurs. Scientists need to innovate with entrepreneurial thinking.Leadingpharm is making the layout of the CXO Industry Chain nationally, including drug evaluation, molecular CDMO、 cell and gene therapy service platform, to help innovative enterprises to create a closed loop. At the same time, providing service units for relatively traditional pharmaceutical enterprises to help them complete the project landing more efficiently and with high quality. Guests and their companies are the integral part of the industrial chain and supply chain of Leadingpharm CXO. Leadingpharm looks forward to working with all pharmaceutical colleagues to enhance communication and understanding, work together for development, and contribute to the realization of the Dream of Healthy China. Finally, Tao also expressed his views and suggestions on the online live broadcast on the previous day, which is about the project approval. He pointed out that each enterprise should carry out differentiated projects according to its own conditions, do a good job in the top-level design of the product pipelines, and enhance the competitiveness of enterprises.

Wang Bo, founder of Pharnex, introduced the situation of Pharnex. He pointed out that Pharnex has developed based on two sections, the flow layer and the commercial layer.Pharnex made differentiated operation, especially based on its strong data capabilities and the planning window of brand publicity, providing full life cycle services for enterprises, constantly extending tentacles and widening service points. He pointed out that the corporate culture and strategic layout of Pharnex were highly consistent with Leadingpharm. He hoped that in the future, the two sides can strengthen interaction, work together to break the barriers between upstream and downstream enterprises, and provide better service for pharmaceutical enterprises.

Huang Qili, Chairman of Inokai; Yang Hua, CEO of Qingsong Medical; Jin Ritian, General Manager of Evershine Asia-Pacific; Huang Wenhua, General Manager of Nanomab China;  Wang Ning, General Manager of Beijing Zhongshuo Pharmaceutical Technology; Wu Xiaowei, Director of Qianwang Medicine and leaders of other enterprises attended the event. The atmosphere was quite warm, guests introduced their respective enterprises respectively. They expressed the hope of making deep communication in the future, concentrate efforts, seek common development, and jointly contribute to the development of China's medical and health industry.
 

-END-